This website uses cookies
Read our Privacy policy and Terms of use for more information.
Jun 9, 2026
Open source developers are close to bringing the Omnipod 5 and Tandem Mobi insulin pumps to open source apps later this year.
Results from two Insulet studies presented at ADA point toward an automated future that demands less from the people using it.
Jun 3, 2026
Insulet is bringing a new target glucose of 100 mg/dL to Omnipod 5 to improve time in range and upgrades to increase time in automated mode.
May 27, 2026
An estimated 7 million pods fall within the scope of this correction, in the U.S. and international markets, representing about 8.5% of 2025 global Pod production.
May 4, 2026
Insulet has enrolled its first participant in its EVOLVE trial testing an automated system designed to eliminate mealtime bolus announcements for people with type 2 diabetes.
Apr 30, 2026
The FDA has classified a Class I recall for certain Omnipod 5 lots after a tubing defect was linked to 476 serious injuries.
Mar 13, 2026
Approximately 1.5% of Omnipod 5 pods are impacted by a tubing issue that may cause insulin to leak inside the device.
Mar 12, 2026
Results from the EVOLUTION 2 trial presented at ATTD showed 68% time in range using a fully closed-loop system—with no mealtime boluses and minimal time below range.
Feb 6, 2026
Insulet's highly anticipated data platform, Omnipod Discover, is available to healthcare providers and Omnipod users across the Middle East.
